Search Results

You are looking at 1 - 10 of 221 items for :

  • "cytotoxic chemotherapy" x
  • Refine by Access: All x
Clear All
Full access

Rational Use of Cytotoxic Chemotherapy for Recurrent Ovarian Cancer

Joyce Liu and Ursula Matulonis

Ovarian cancer remains the leading cause of death among women with gynecologic malignancies, and the fifth leading cause of cancer mortality in women in the United States. Although many patients respond to first-line platinum-based therapy, most will experience disease recurrence. The role of further therapy in the setting of recurrent ovarian cancer is palliative, and large randomized phase III trials on treatment options for recurrent ovarian cancer are rare. Controversies exist as to the optimal timing and duration of treatment, and many issues regarding treatment of recurrent disease remain.

Full access

New First-Line Systemic Treatment Options for Metastatic Esophageal Squamous Cell Carcinoma

Presented by: Michael K. Gibson

For many years, treatment options for patients with metastatic esophageal squamous cell carcinoma (SCC) were few, and survival rates were low. Combination cytotoxic chemotherapy regimens afforded patients roughly another year of survival at most

Full access

Emerging Treatments in Recurrent and Metastatic Colorectal Cancer

Kristen Keon Ciombor and Tanios Bekaii-Saab

combinations of these agents in addition to fluoropyrimidines led to significant improvement in overall survival. In general, doublet cytotoxic chemotherapy regimens have been effective and tolerable as palliative therapy for mCRC, and many standard options

Full access

Management of Patients With Aggressive Nonmelanoma Skin Cancers

Presented by: Valencia D. Thomas, Michael K. Wong, and Andrew J. Bishop

A wide range of approaches exist for treating aggressive nonmelanoma skin cancers, including surgery, radiation therapy (RT), cytotoxic chemotherapy, systemic immunotherapy, and active surveillance. Selecting an appropriate therapeutic approach

Full access

Breast Cancer Version 2.2015

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew Goetz, Lori J. Goldstein, Clifford A. Hudis, Steven J. Isakoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena Moran, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dorothy A. Shead, and Rashmi Kumar

children after breast cancer therapy. 24 – 28 No high-level evidence demonstrates that ovarian suppression or other interventions decrease the toxicity of cytotoxic chemotherapy on the premenopausal ovary. 29 However, many women, especially those younger

Full access

Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancers

Helena A. Yu and Gregory J. Riely

platinum-based chemotherapy, and gefitinib led to improved PFS and objective response rates compared with cytotoxic chemotherapy in patients with EGFR mutations. Similar to gefitinib, erlotinib was also compared with placebo in patients with advanced

Full access

Optimizing Therapy for Acute Myeloid Leukemia

Holbrook E. Kohrt and Steven E. Coutre

>= age 70 who are not candidates for traditional cytotoxic chemotherapy (TCC) [abstract] . Blood 2006 ; 108 : Abstract 426 . 81. List AF Kopecky KJ Willman CL . Benefit of cyclosporine modulation of drug resistance in patients with poor

Full access

Management of the Primary Tumor and Limited Metastases in Patients With Metastatic Pancreatic Cancer

Joseph M. Herman, John P. Hoffman, Sarah P. Thayer, and Robert A. Wolff

. Fourth, image-guided percutaneous radiofrequency ablation (RFA) and laparoscopically assisted RFA may allow for management of limited metastatic disease and spare patients the toxicity associated with ongoing cytotoxic chemotherapy. Lastly, the

Full access

Breast Cancer Version 3.2014

William J. Gradishar, Benjamin O. Anderson, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, Daniel F. Hayes, Clifford A. Hudis, Steven J. Isakoff, Britt-Marie E. Ljung, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Robert S. Miller, Mark Pegram, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Mary Lou Smith, Hatem Soliman, George Somlo, John H. Ward, Antonio C. Wolff, Richard Zellars, Dorothy A. Shead, and Rashmi Kumar

Approach Conceptually, the treatment of breast cancer includes the treatment of local disease with surgery, radiation therapy, or both, and the treatment of systemic disease with cytotoxic chemotherapy, endocrine therapy, biologic therapy, or combinations

Full access

A Randomized Phase II Study of Cetuximab Every 2 Weeks at Either 500 or 750 mg/m2 for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Matthew G. Fury, Eric Sherman, Donna Lisa, Neeraj Agarwal, Kenneth Algazy, Bruce Brockstein, Corey Langer, Dean Lim, Ranee Mehra, Sandeep K. Rajan, Susan Korte, Brynna Lipson, Furhan Yunus, Tawee Tanvetyanon, Stephanie Smith-Marrone, Kenneth Ng, Han Xiao, Sofia Haque, and David G. Pfister

) has been evaluated both as monotherapy and in combination with cytotoxic chemotherapy. 5 Cetuximab weekly monotherapy for patients with advanced platinum-refractory HNSCC yielded objective radiographic responses rates of 10% to 13% in phase II